Dupixent (dupilumab) is a brand-name injection that’s ... Dupixent and several other biologic medications approved as add-on medications for treating asthma are recognized as treatment options ...

Eosinophilic asthma (also known as e-asthma or ... Your healthcare provider may prescribe biologic drugs via subcutaneous injections (under the skin) or intravenous administration (through a ...

Patients without vs. with previous biologic use had a greater relative reduction in annualized exacerbation rate. Among adults with severe eosinophilic asthma and previous biologic use ...

BOSTON — Patients with obesity and asthma may see reductions in exacerbations with biologic treatment, according to a presentation at the CHEST Annual Meeting. “Obesity and asthma have ...

Nov. 27, 2024 — A recent trial finds an injection given during some asthma and COPD attacks is more effective than the current treatment of steroid tablets, reducing the need for further ...

GSK plc (LSE/NYSE: GSK), a prominent pharmaceutical company with a market capitalization of $71.31 billion and an impressive gross profit margin of 72.39%, has announced that its new drug applications ...

Denmark: A recent study published in The Journal of Allergy and Clinical Immunology: In Practice found that ex-smokers with severe asthma respond to biologic treatments as effectively as never-smokers ...

GSK plc (LSE/NYSE: GSK) today announced that new drug applications have been accepted for review by the China National Medical Products Administration and submitted to the Japanese Ministry of Health, ...

Intermediate group 2 innate lymphoid cells (ILC2s) appear to be able to get around cutting-edge asthma treatments by transforming into another type of immune cell. Targeted biologic drugs have ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency has accepted for review the Marketing Authorisation Application for the use of depemokimab in two indications. The submitted ...

London: GSK plc has announced that the European Medicines Agency (EMA) has accepted for review the Marketing Authorisation ...

GSK announces depemokimab applications accepted for review in China and Japan for asthma with type 2 inflammation and CRSwNP: London, UK Wednesday, January 29, 2025, 17:00 Hrs [IS ...